Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Retained Earnings: 2017-2024

Historic Retained Earnings for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Dec 2024 value amounting to -$952.1 million.

  • Crinetics Pharmaceuticals' Retained Earnings fell 49.17% to -$1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year decrease of 49.17%. This contributed to the annual value of -$952.1 million for FY2024, which is 45.65% down from last year.
  • Per Crinetics Pharmaceuticals' latest filing, its Retained Earnings stood at -$952.1 million for FY2024, which was down 45.65% from -$653.7 million recorded in FY2023.
  • Crinetics Pharmaceuticals' 5-year Retained Earnings high stood at -$167.6 million for FY2020, and its period low was -$952.1 million during FY2024.
  • For the 3-year period, Crinetics Pharmaceuticals' Retained Earnings averaged around -$681.7 million, with its median value being -$653.7 million (2023).
  • Data for Crinetics Pharmaceuticals' Retained Earnings shows a maximum YoY plummeted of 78.69% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Crinetics Pharmaceuticals' Retained Earnings stood at -$167.6 million in 2020, then tumbled by 64.22% to -$275.3 million in 2021, then slumped by 59.55% to -$439.2 million in 2022, then plummeted by 48.85% to -$653.7 million in 2023, then crashed by 45.65% to -$952.1 million in 2024.